Üremide Metabolizma Değişiklikleri

Yıl 2011, Cilt: 08 Sayı: 1, 36 - 41, 30.06.2011

Feray Gökdoğan

Öz

Üremi, böbrek fonksiyonlarında ilerleyici bozulma sonucunda

sıvı-elektrolit, hormon dengesizlikleri ve metabolik

anormallikler gelişen klinik bir sendromdur. Böbreklerde yaşamsal

bazı metabolik düzenleyicilerin (eritropoetin, aktif D

vitamini vb) sentezinin bozulması da bu değişikliklere önemli

katı› sağlar. Diyaliz öncesi ve diyaliz tedavisi sırasında

tüm bu faktörler atheroskleroz gelişlimi, kardiyovasküler hastalı

k, malnütrisyon, anemi, renal osteodistrofi, hiperparatiroidizm

vb. çok ciddi komplikasyonlar›n yanı sıra, hastaların

yaşam kalitesini ve prognozu önemli derecede etkileyen ciddi

sorunlara yol açar. Böbrek hastalıkları erken dönemde tanımlanır

 ve komplikasyonlar erken dönemde tedavi edilirse,

hastalığın seyri iyileştirilebilir ve maliyeti azaltılabilir.

Anahtar Kelimeler

Üremi, Metabolik değişiklikler, Komplikasyonlar

Kaynakça

• 1. Alper AB, Shenava RG. Uremia. March 17 2010. http://www.medscape.com (Eriflim Tarihi: 31.08.2010).
• 2. Carrero JJ, Witasp A, Stenvinkel P, et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant. Mar 2010;25(3):901-6. Üremide Metabolizma De¤ifliklikleri
• 3. Levey AS, Atkins R, Coresh J , Cohen EP , Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M,Levin A, Powe1 NR, Rossert J, Wheeler DC, Lameire N and Eknoyan G. Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney International advance online publication, 13 June 2007; 1-13.
• 4. Cibulka R, Racek J, Vesela E. The importance of L-carnitine in patients with chronic renal failure treated with hemodialysis (in Czech). Vnitr Lek 2007;.51: 1108-1113.
• 5. Cibulka R, Racek J. Metabolic Disorders in Patients with Chronic Kidney Failure Physiol. Res. 2007;56: 697-705.
• 6. Silver J: Molecular mechanisms of secondary hyperparathyroidism. Nephrol Dial Transplant 2000;15: 2-7.
• 7. Porth CM. Pathophysiology Concepts of Altered Health States. 6th ed. Philadelphia, Pa: Lippincott; 2002.
• 8. Price S, Wilson L. Pathophysiology: Clinical Concepts of Disease Processes. 6th ed. St Louis, Mo: Mosby; 2003.
• 9. Metheny N. Fluid and Electrolyte Balance. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000.
• 10. Wallace M. Anatomy and physiology of the kidney. AORN J. 1998; 68:799-780, 803-804, 806, 808, 810-811, 813-816, 819-824, 827-828.
• 11. Ik›zler TA, W›ndgard RL, Harvell J, Shyr Y, Hak›m RM: Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999; 55: 1945-1951.
• 12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: guideline, assessment of proteinuria. Available at: http://www.kidney.org /professionals/kdoqi/guide lines_ckd /p5_lab_g5.htm. (Eriflim Tarihi 15.05. 2006).
• 13. Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int Suppl 62: S48-S52, 1997.
• 14. Rigalleau V, Gin H: Carbohydrate metabolism in uremia. Curr Opin Clin Nutr Metab Care 2005; 8: 463-869.
• 15. Shinohara K, Shoj› T, Emoto M, Tahara H, Koyama H, Ish›mura E, M›k› T, Tabata T, N›sh›zawa Y: Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894-1900.
• 16. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod P, Thorens B, Scherrer U: Insulin resistance, hyperlipidemia and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001; 104: 342-345.
• 17. Dirican M, Akça R, Sarandol E, Dilek K: Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 2004; 17: 813-818.
• 18. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md. Available at: http:// www.usrds.org/atlas.htm. (Eriflim Tarihi 15.05.2006).
• 19. Broscious SK, Castagnola J. Chronic Kidney Disease Acute Manifestations and Role of Critical Care Nurses Cr›t›cal Care Nurse August 2006; Vol 26, No. 4.
• 20. Heuther SE, McCance KL. Understanding Pathophysiology. 3rd ed. St Louis, Mo: Mosby; 2004.
• 21. Snyder S, Pendergraph B: Detection and evaluation of chronic kidney disease. Am Fam Physician 2005; 72: 1723-1732.
• 22. Nat›onal K›dney Foundat›on: K/DOQI, clinical practice guidelines for managing dyslipidemias in chronic kidney disease, part 3, guideline 4. 2006. http://www.kidney.org/professionals/kdoqi/guidelines_lipids/iii.htm.
• 23. Diabetes and Digestive and Kidney Diseases, Bethesda, Md. Available at: http:// www.usrds.org/atlas.htm. (Eriflim Tarihi: 15.05.2006).